Sign up to receive more information about NIASPAN and issues relevant to your practice. Learn More »
Niacin and hyperglycemia
Using Niacin in Diabetic Patients
ADA/AHA guidelines suggest that niacin is very effective for raising HDL-C levels. At higher doses, niacin can worsen hyperglycemia, but glycemic control may be maintained with appropriate adjustment of diabetes therapy and moderate doses of niacin (≤3 g/day).1,2
Guidance from NIASPAN (niacin prescribing information)
Diabetic patients may experience a dose-related rise in glucose intolerance, the clinical significance of which is unclear. Diabetic or potentially diabetic patients should be observed closely. Adjustment of diet and/or hypoglycemic therapy may be necessary.3
When using NIASPAN in your diabetic patients, consider MONITORING their glycemic status, MODIFYING their glucose treatment regimens or NIASPAN dosage as needed, and MAINTAINING their glycemic control.
Clinical Trial Results With Niacin in Patients With Diabetes
Next: Professional Web Links
References
1. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(suppl 1):S33-S49.
2. Buse JB, Ginsberg HN, Bakris GL. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-172.
3. NIASPAN® prescribing information. North Chicago, IL; Abbott Laboratories.
4. Grundy SM, Vega GL, McGovern ME, et al; for the Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of one-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162(14):1568-1576.
5. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control iin patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA. 2000;284(10):1263-1270.
